Holen Sie sich die Stockscreener-App
0.738
0.35%
-0.0026
Schlusskurs vom Vortag:
$0.7406
Offen:
$0.74
24-Stunden-Volumen:
209.64K
Relative Volume:
0.57
Marktkapitalisierung:
$23.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.23M
KGV:
-0.5722
EPS:
-1.2898
Netto-Cashflow:
$-41.53M
1W Leistung:
-4.28%
1M Leistung:
-7.69%
6M Leistung:
-81.55%
1J Leistung:
-71.72%
1-Tages-Spanne:
$0.7345
$0.7775
1-Wochen-Bereich:
$0.721
$0.80
52-Wochen-Spanne:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.50 | 350.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.26 | 465.95M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.18 | 372.90M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
45.25 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
103.33 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-15 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - GlobeNewswire
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-02-17 | Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Aug Movers: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARWeekly Trade Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-02-15 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
How do insiders feel about Skye Bioscience Inc.Dividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
SKYE Should I Buy - Intellectia AI
What’s the outlook for Skye Bioscience Inc.’s sector2025 Trade Ideas & AI Forecasted Entry and Exit Points - mfd.ru
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
SKYE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
A | Can Atmos Energy Corporation (AEO) stock retain market dominanceEarnings Overview Summary & Expert Curated Trade Setup Alerts - mfd.ru
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Skye Bioscience Inc. stock reach $100 price targetWeekly Trade Analysis & Technical Confirmation Trade Alerts - mfd.ru
Skye Bioscience (SKYE) director receives grant of 35,000 options - Stock Titan
Skye Bioscience (SKYE) grants CEO 280,000 stock options at $0.82 - Stock Titan
Whats the outlook for Skye Bioscience Incs sectorTrade Analysis Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Retail Trends: Does Skye Bioscience Inc have a competitive edgeJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Aug Analyst Calls: Will Skye Bioscience Inc benefit from government policy2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Movement Recap: Can Skye Bioscience Inc weather a recessionMarket Rally & Long-Term Capital Growth Strategies - baoquankhu1.vn
Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Sahm
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com Australia
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating - TipRanks
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab - TipRanks
Skye reports positive Cbeyond phase 2a extension interim study results for nimacimab - marketscreener.com
Skye Bioscience Reports Interim Results from Phase 2a Study of Nimacimab - TradingView
Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab - marketscreener.com
Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan
Chart Watch: Can Skye Bioscience Inc weather a recessionWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Skye Bioscience reports positive results for obesity drug nimacimab By Investing.com - Investing.com South Africa
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):